Key points are not available for this paper at this time.
Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
Share your take
Add a clinician perspective alongside expert commentary.
Ghia et al. (2020) studied this question.